Preclinical studies on a low molecular weight heparin

Area of Science:

• Pharmacology
• Thrombosis Research
• Drug Development

Background:

• Antithrombotic therapy has seen major advancements, notably with low molecular weight heparins (LMWHs).
• LMWHs are now standard for preventing deep vein thrombosis (DVT) post-surgery and are explored for cardiovascular uses.
• Reviparin is an optimized LMWH derived from porcine mucosal heparin via controlled nitrous acid digestion.

Purpose of the Study:

• To characterize the molecular profile and pharmacological effects of Reviparin.
• To investigate Reviparin's dose- and time-dependent antithrombotic activity and TFPI release.
• To compare Reviparin's pharmacological profile with other LMWHs like nadroparin and enoxaparin.

Main Methods:

• Controlled nitrous acid digestion of heparin to produce Reviparin.
• Anticoagulant and anti-Xa activity assays.
• Animal models of thrombosis to assess antithrombotic effects.
• Primate model for evaluating TFPI release after intravenous and subcutaneous administration.
• Comparative pharmacological studies with nadroparin and enoxaparin.

Main Results:

• Reviparin exhibits a narrow molecular weight distribution and specific activities of 32 U/mg and 120 anti-Xa U/mg.
• Dose- and time-dependent antithrombotic effects were observed in animal models.
• Sustained antithrombotic effects occurred without significant ex vivo anticoagulant actions.
• Reviparin administration led to the release of tissue factor pathway inhibitor (TFPI).
• Repeated administration showed progressively stronger antithrombotic effects.

Conclusions:

• Reviparin is an optimized LMWH with a distinct molecular profile and pharmacological properties.
• It demonstrates effective and sustained antithrombotic activity, partly through TFPI release.
• Further studies confirm its potential in managing thromboembolic disorders, with comparative data against other LMWHs.